Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
dc.contributor.author | Siafis, Spyridon | |
dc.contributor.author | Rodolico, Alessandro | |
dc.contributor.author | Çıray, Oğulcan | |
dc.contributor.author | Murphy, Declan G. | |
dc.contributor.author | Parellada Redondo, María José | |
dc.contributor.author | Arango López, Celso | |
dc.contributor.author | Leucht, Stefan | |
dc.date.accessioned | 2023-06-16T14:20:34Z | |
dc.date.available | 2023-06-16T14:20:34Z | |
dc.date.issued | 2021-07-09 | |
dc.description.abstract | Introduction: Response to treatment, according to Clinical Global Impression-Improvement (CGI-I) scale, is an easily interpretable outcome in clinical trials of autism spectrum disorder (ASD). Yet, the CGI-I rating is sometimes reported as a continuous outcome, and converting it to dichotomous would allow meta-analysis to incorporate more evidence. Methods: Clinical trials investigating medications for ASD and presenting both dichotomous and continuous CGI-I data were included. The number of patients with at least much improvement (CGI-I ≤ 2) were imputed from the CGI-I scale, assuming an underlying normal distribution of a latent continuous score using a primary threshold θ = 2.5 instead of θ = 2, which is the original cut-off in the CGI-I scale. The original and imputed values were used to calculate responder rates and odds ratios. The performance of the imputation method was investigated with a concordance correlation coefficient (CCC), linear regression, Bland–Altman plots, and subgroup differences of summary estimates obtained from random-effects meta-analysis. Results: Data from 27 studies, 58 arms, and 1428 participants were used. The imputation method using the primary threshold (θ = 2.5) had good performance for the responder rates (CCC = 0.93 95% confidence intervals [0.86, 0.96]; β of linear regression = 1.04 [0.95, 1.13]; bias and limits of agreements = 4.32% [−8.1%, 16.74%]; no subgroup differences χ2 = 1.24, p-value = 0.266) and odds ratios (CCC = 0.91 [0.86, 0.96]; β = 0.96 [0.78, 1.14]; bias = 0.09 [−0.87, 1.04]; χ2 = 0.02, p-value = 0.894). The imputation method had poorer performance when the secondary threshold (θ = 2) was used. Discussion: Assuming a normal distribution of the CGI-I scale, the number of responders could be imputed from the mean and standard deviation and used in meta-analysis. Due to the wide limits of agreement of the imputation method, sensitivity analysis excluding studies with imputed values should be performed. | |
dc.description.department | Depto. de Medicina Legal, Psiquiatría y Patología | |
dc.description.faculty | Fac. de Medicina | |
dc.description.refereed | TRUE | |
dc.description.sponsorship | Unión Europea. Horizonte 2020 | |
dc.description.sponsorship | Innovative Medicines Initiative 2 | |
dc.description.status | pub | |
dc.eprint.id | https://eprints.ucm.es/id/eprint/70877 | |
dc.identifier.doi | 10.3390/brainsci11070908 | |
dc.identifier.issn | 2076-3425 | |
dc.identifier.officialurl | https://doi.org/10.3390/brainsci11070908 | |
dc.identifier.relatedurl | https://www.mdpi.com/2076-3425/11/7/908/htm | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/4749 | |
dc.issue.number | 7 | |
dc.journal.title | Brain Sciences | |
dc.language.iso | eng | |
dc.page.initial | 908 | |
dc.publisher | MPDI | |
dc.relation.projectID | AIMS-2-TRIALS (777394) | |
dc.relation.projectID | EFPIA, AUTISM SPEAKS, Autistica | |
dc.rights | Atribución 3.0 España | |
dc.rights.accessRights | open access | |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject.keyword | response | |
dc.subject.keyword | meta-analysis | |
dc.subject.keyword | continuous outcomes | |
dc.subject.keyword | dichotomous outcomes | |
dc.subject.ucm | Neurociencias (Medicina) | |
dc.subject.ucm | Psiquiatría | |
dc.subject.unesco | 2490 Neurociencias | |
dc.subject.unesco | 3211 Psiquiatría | |
dc.title | Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder | |
dc.type | journal article | |
dc.volume.number | 11 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 5d8b0c5e-f48f-465e-86d2-803745e403f8 | |
relation.isAuthorOfPublication | 23fb749e-1a82-4838-8fea-01d964b22093 | |
relation.isAuthorOfPublication.latestForDiscovery | 5d8b0c5e-f48f-465e-86d2-803745e403f8 |
Download
Original bundle
1 - 1 of 1